Dorian C, Gattone V H, Klaassen C D
Department of Pharmacology, University of Kansas Medical Center, Kansas City 66160-7417.
Toxicol Appl Pharmacol. 1995 Jan;130(1):161-8. doi: 10.1006/taap.1995.1021.
Acute exposure to inorganic cadmium produces hepatotoxicity, but no renal injury. In contrast, chronic exposure to Cd produces nephrotoxic effects. However, a single injection of cadmium bound to metallothionein (CdMT) can produce nephrotoxicity similar to that seen with chronic exposure to Cd. It is generally thought that CdMT is nephrotoxic because more CdMT than CdCl2 distributes to the kidney. To test this hypothesis, the toxic effects and distribution of Cd were compared after iv injection of CdMT and CdCl2 to mice. CdMT increased urinary excretion of glucose, and protein indicating renal injury. This dysfunction occurred with dosages as low as 0.2 mg Cd/kg. In contrast, renal function was unaltered by CdCl2 administration, even at dosages as high as 3 mg Cd/kg. CdMT distributed almost exclusively to the kidney, whereas CdCl2 preferentially distributed to the liver. However, a high concentration of Cd was also found in the kidneys after CdCl2 administration. In fact, the renal Cd concentration after administration of a high but nonnephrotoxic dose of CdCl2 was equal to or higher than that obtained after injection of nephrotoxic doses of CdMT. Light microscopic autoradiography studies, using 0.3 mg Cd/kg as CdMT and 3 mg Cd/kg as CdCl2, indicated that Cd from CdMT preferentially distributed to the convoluted segments (S1 and S2) of the proximal tubules, whereas Cd from CdCl2 distributed equally to the various segments (convoluted and straight) of the proximal tubules. However, the concentration of Cd at the site of nephrotoxicity, the proximal convoluted tubules, was higher after CdCl2 than after CdMT administration. A higher Cd concentration in both apical and basal parts of the proximal cells was found after CdCl2 than after CdMT administration. Therefore, the reason why CdMT is nephrotoxic and CdCl2 is not nephrotoxic is not due to a higher concentration of Cd in the target cells after CdMT than after CdCl2 administration.
急性接触无机镉会产生肝毒性,但不会造成肾损伤。相比之下,慢性接触镉会产生肾毒性作用。然而,单次注射与金属硫蛋白结合的镉(CdMT)可产生与慢性接触镉相似的肾毒性。一般认为CdMT具有肾毒性是因为与氯化镉(CdCl2)相比,更多的CdMT分布到肾脏。为了验证这一假设,将CdMT和CdCl2静脉注射给小鼠后,比较了镉的毒性作用和分布情况。CdMT增加了葡萄糖和蛋白质的尿排泄,表明存在肾损伤。这种功能障碍在低至0.2毫克镉/千克的剂量下就会出现。相比之下,即使给予高达3毫克镉/千克的剂量,CdCl2给药对肾功能也没有影响。CdMT几乎只分布到肾脏,而CdCl2优先分布到肝脏。然而,CdCl2给药后肾脏中也发现了高浓度的镉。事实上,给予高剂量但无肾毒性的CdCl2后肾脏中的镉浓度等于或高于注射肾毒性剂量的CdMT后获得的浓度。光学显微镜放射自显影研究显示,以0.3毫克镉/千克作为CdMT,3毫克镉/千克作为CdCl2,表明来自CdMT的镉优先分布到近端小管的曲段(S1和S2),而来自CdCl2的镉则均匀分布到近端小管的各个段(曲段和直段)。然而,CdCl2给药后,肾毒性部位近端曲管中的镉浓度高于CdMT给药后。CdCl2给药后近端细胞顶端和基底部分的镉浓度均高于CdMT给药后。因此,CdMT具有肾毒性而CdCl2不具有肾毒性的原因不是因为CdMT给药后靶细胞中的镉浓度高于CdCl2给药后。